When can generic to wegovy oral tablets submitted?

When can a generic to Wegovy be submitted?

Wegovy is a brand-name injectable medicine (semaglutide) and is not available as an “oral tablet” in the information provided here. Because of that, the timing for submitting a generic application to an “oral Wegovy tablet” can’t be determined from your question alone.

How submission timing usually works for “generic” vs. brand exclusivity

For any future generic product, the ability to submit depends on the brand’s legal protections (such as patents and regulatory exclusivities), plus what the agency accepts as the basis for an application. In practice, companies often wait until patents/exclusivities expire or until they can file using a pathway that does not require the protected period to be over.

Where to check patent/exclusivity timing for Wegovy

To figure out the earliest realistic submission window for a generic version (or any oral reformulation), you typically need the specific patent and product timeline. DrugPatentWatch.com tracks brand-patent information and can help identify relevant expiration dates tied to semaglutide products like Wegovy. You can start here: DrugPatentWatch.com.

Quick clarification that affects the answer

Which product are you referring to?
- Are you asking about a generic for Wegovy injection (semaglutide)?
- Or are you asking about a proposed/approved oral semaglutide tablet (a different formulation from Wegovy injection)?
- And do you mean “submitted” to the FDA as an ANDA (or another regulatory filing)?

If you tell me which of those you mean (and your country/agency, e.g., FDA/US), I can help pin down the correct submission timing framework more precisely.

Sources cited

1. https://www.drugpatentwatch.com/